Protalix BioTherapeutics to Participate in Upcoming Investor Conferences

CARMIEL, Israel, Sept. 8, 2026 /CourierPR/ -- Protalix BioTherapeutics, a biopharmaceutical company focused on developing innovative therapeutics for rare diseases, will participate in two upcoming investor conferences in September 2026. According to the company, Gilad Mamlok, the Senior Vice President and Chief Financial Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference and participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference.

At the H.C. Wainwright conference, Mamlok will deliver a company presentation on Monday, September 14, 2026, at 2:00 p.m. EDT. The event is scheduled to take place in New York City. Meanwhile, on Wednesday, September 16, 2026, Mamlok will engage in a fireside chat at the Morgan Stanley conference, also held in New York, at 1:05 p.m. EDT. An archived replay of the Morgan Stanley fireside chat will be available on the company's website.

Protalix BioTherapeutics is known for its innovative plant cell-based expression system, ProCellEx, which has enabled the company to develop two enzyme replacement therapies. Currently, the company's product, Elfabrio (pegunigalsidase alfa-iwxj), is approved for Fabry disease in the United States, the European Union, and additional markets, and it is partnered with Chiesi Global Rare Diseases. Additionally, Elelyso (taliglucerase alfa) for Gaucher disease is approved in 23 markets and is partnered with Pfizer Inc. worldwide, with the exception of Brazil, where the company partners with Fundação Oswaldo Cruz, an arm of the Brazilian Ministry of Health.

The company's development portfolio includes PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout, currently in Phase 2 trials. Other ongoing research programs include PRX-119, a plant cell-expressed long-acting DNase I for the treatment of NETs-related diseases. Protalix is also exploring rare renal diseases through its research programs.

These upcoming investor conferences will provide a platform for investors and analysts to gain insights into Protalix BioTherapeutics' strategic direction and recent developments. The company's participation in these events is expected to attract significant interest from the investment community and strengthen its position in the rare disease market.